Prophylactic	prophylactic	O	O
use	use	O	O
of	of	O	O
lamivudine	lamivudine	S_chemical	O
with	with	O	O
chronic	chronic	O	O
immunosuppressive	immunosuppressive	O	O
therapy	therapy	O	O
for	for	O	O
rheumatologic	rheumatologic	O	O
disorders	disorders	O	O
.	.	O	O

The	the	O	O
objective	objective	O	O
of	of	O	O
this	this	O	O
study	study	O	O
was	was	O	O
to	to	O	O
report	report	O	O
our	our	O	O
experience	experience	O	O
concerning	concerning	O	O
the	the	O	O
effectiveness	effectiveness	O	O
of	of	O	O
the	the	O	O
prophylactic	prophylactic	O	O
administration	administration	O	O
of	of	O	O
lamivudine	lamivudine	S_chemical	O
in	in	O	O
hepatitis	hepatitis	O	B_disease
B	b	O	I_disease
virus	virus	O	O
surface	surface	O	O
antigen	antigen	O	O
(	(	O	O
HBs	hbs	O	O
Ag	ag	O	O
)	)	O	O
positive	positive	O	O
patients	patients	O	O
with	with	O	O
rheumatologic	rheumatologic	O	O
disease	disease	O	O
.	.	O	O

From	from	O	O
June	june	O	O
2004	2004	O	O
to	to	O	O
October	october	O	O
2006	2006	O	O
,	,	O	O
11	11	O	O
HBs	hbs	O	O
Ag	ag	O	O
positive	positive	O	O
patients	patients	O	O
with	with	O	O
rheumatologic	rheumatologic	O	O
diseases	diseases	O	O
,	,	O	O
who	who	O	O
were	were	O	O
on	on	O	O
both	both	O	O
immunosuppressive	immunosuppressive	O	O
and	and	O	O
prophylactic	prophylactic	O	O
lamivudine	lamivudine	S_chemical	O
therapies	therapies	O	O
,	,	O	O
were	were	O	O
retrospectively	retrospectively	O	O
assessed	assessed	O	O
.	.	O	O

Liver	liver	O	O
function	function	O	O
tests	tests	O	O
,	,	O	O
hepatitis	hepatitis	O	B_disease
B	b	O	I_disease
virus	virus	O	O
(	(	O	O
HBV	hbv	O	O
)	)	O	O
serologic	serologic	O	O
markers	markers	O	O
,	,	O	O
and	and	O	O
HBV	hbv	O	O
DNA	dna	O	O
levels	levels	O	O
of	of	O	O
the	the	O	O
patients	patients	O	O
during	during	O	O
follow-up	follow-up	O	O
were	were	O	O
obtained	obtained	O	O
from	from	O	O
hospital	hospital	O	O
file	file	O	O
records	records	O	O
.	.	O	O

Eleven	eleven	O	O
patients	patients	O	O
(	(	O	O
six	six	O	O
male	male	O	O
)	)	O	O
with	with	O	O
median	median	O	O
age	age	O	O
47	47	O	O
years	years	O	O
(	(	O	O
range	range	O	O
27	27	O	O
-	-	O	O
73	73	O	O
)	)	O	O
,	,	O	O
median	median	O	O
disease	disease	O	O
duration	duration	O	O
50	50	O	O
months	months	O	O
(	(	O	O
range	range	O	O
9	9	O	O
-	-	O	O
178	178	O	O
)	)	O	O
and	and	O	O
median	median	O	O
follow-up	follow-up	O	O
period	period	O	O
of	of	O	O
patients	patients	O	O
13.8	13.8	O	O
months	months	O	O
(	(	O	O
range	range	O	O
5	5	O	O
-	-	O	O
27	27	O	O
)	)	O	O
were	were	O	O
enrolled	enrolled	O	O
in	in	O	O
this	this	O	O
study	study	O	O
.	.	O	O

Lamivudine	lamivudine	S_chemical	O
therapy	therapy	O	O
was	was	O	O
started	started	O	O
3	3	O	O
-	-	O	O
7	7	O	O
days	days	O	O
prior	prior	O	O
to	to	O	O
immunosuppressive	immunosuppressive	O	O
therapy	therapy	O	O
in	in	O	O
all	all	O	O
patients	patients	O	O
.	.	O	O

Baseline	baseline	O	O
,	,	O	O
liver	liver	O	O
function	function	O	O
tests	tests	O	O
were	were	O	O
elevated	elevated	O	O
in	in	O	O
two	two	O	O
patients	patients	O	O
(	(	O	O
fourth	fourth	O	O
patient	patient	O	O
:	:	O	O
ALT:122	alt:122	O	O
IU/l	iu/l	O	O
,	,	O	O
AST:111	ast:111	O	O
IU/l	iu/l	O	O
,	,	O	O
tenth	tenth	O	O
patient	patient	O	O
:	:	O	O
ALT:294	alt:294	O	O
IU/l	iu/l	O	O
,	,	O	O
AST:274	ast:274	O	O
IU/l	iu/l	O	O
,	,	O	O
with	with	O	O
minimal	minimal	O	O
changes	changes	O	O
in	in	O	O
the	the	O	O
liver	liver	O	O
biopsy	biopsy	O	O
in	in	O	O
both	both	O	O
)	)	O	O
.	.	O	O

Shortly	shortly	O	O
after	after	O	O
treatment	treatment	O	O
their	their	O	O
tests	tests	O	O
normalized	normalized	O	O
and	and	O	O
during	during	O	O
follow-up	follow-up	O	O
period	period	O	O
none	none	O	O
of	of	O	O
the	the	O	O
patients	patients	O	O
had	had	O	O
abnormal	abnormal	O	O
liver	liver	O	O
function	function	O	O
tests	tests	O	O
.	.	O	O

In	in	O	O
four	four	O	O
patients	patients	O	O
HBV	hbv	O	O
DNA	dna	O	O
levels	levels	O	O
were	were	O	O
higher	higher	O	O
than	than	O	O
normal	normal	O	O
at	at	O	O
baseline	baseline	O	O
.	.	O	O

Two	two	O	O
of	of	O	O
these	these	O	O
normalized	normalized	O	O
and	and	O	O
the	the	O	O
others	others	O	O
increased	increased	O	O
later	later	O	O
.	.	O	O

In	in	O	O
three	three	O	O
additional	additional	O	O
patients	patients	O	O
,	,	O	O
HBV	hbv	O	O
DNA	dna	O	O
levels	levels	O	O
were	were	O	O
increased	increased	O	O
during	during	O	O
follow-up	follow-up	O	O
.	.	O	O

None	none	O	O
of	of	O	O
the	the	O	O
patients	patients	O	O
had	had	O	O
significant	significant	O	O
clinical	clinical	O	O
sings	sings	O	O
of	of	O	O
HBV	hbv	O	O
activation	activation	O	O
.	.	O	O

Lamivudine	lamivudine	S_chemical	O
was	was	O	O
well	well	O	O
tolerated	tolerated	O	O
and	and	O	O
was	was	O	O
continued	continued	O	O
in	in	O	O
all	all	O	O
patients	patients	O	O
.	.	O	O

Prophylactic	prophylactic	O	O
administration	administration	O	O
of	of	O	O
lamivudine	lamivudine	S_chemical	O
in	in	O	O
patients	patients	O	O
who	who	O	O
required	required	O	O
immunosuppressive	immunosuppressive	O	O
therapy	therapy	O	O
seems	seems	O	O
to	to	O	O
be	be	O	O
safe	safe	O	O
,	,	O	O
well	well	O	O
tolerated	tolerated	O	O
and	and	O	O
effective	effective	O	O
in	in	O	O
preventing	preventing	O	O
HBV	hbv	O	O
reactivation	reactivation	O	O
.	.	O	O

